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Abstract
The hyalinizing trabecular adenoma/tumor is a rare and poorly characterized follicular-derived thyroid neoplasm recently
shown to harbor recurrent PAX8–GLIS1 or PAX8–GLIS3 gene fusions. Here we sought to define the repertoire of genetic
alterations of hyalinizing trabecular tumors, and whether PAX8–GLIS3 fusions are pathognomonic for hyalinizing trabecular
tumors. A discovery series of eight hyalinizing trabecular tumors was subjected to RNA-sequencing (n= 8), whole-exome
sequencing (n= 3) or targeted massively parallel sequencing (n= 5). No recurrent somatic mutations or copy number
alterations were identified in hyalinizing trabecular tumor, whereas RNA-sequencing revealed the presence of a recurrent
genetic rearrangement involving PAX8 (2q14.1) and GLIS3 (9p24.2) genes in all cases. In this in-frame fusion gene, which
comprised exons 1–2 of PAX8 and exons 3–11 of GLIS3, GLIS3 is likely placed under the regulation of PAX8. Reverse
transcription RT-PCR and/or fluorescence in situ hybridization analyses of a validation series of 26 hyalinizing trabecular
tumors revealed that the PAX8–GLIS3 gene fusion was present in all hyalinizing trabecular tumors (100%). No GLIS1
rearrangements were identified. Conversely, no PAX8–GLIS3 gene fusions were detected in a cohort of 237 control thyroid
neoplasms, including 15 trabecular thyroid lesions highly resembling hyalinizing trabecular tumor from a morphological
standpoint, as well as trabecular/solid follicular adenomas, solid/trabecular variants of papillary carcinoma, and Hurthle cell
adenomas or carcinomas. Our data provide evidence to suggest that the PAX8–GLIS3 fusion is pathognomonic for
hyalinizing trabecular tumors, and that the presence of the PAX8–GLIS3 fusion in thyroid neoplasms may be used as an
ancillary marker for the diagnosis of hyalinizing trabecular tumor, thereby avoiding overtreatment in case of misdiagnoses
with apparently similar malignant tumors.
Introduction
Hyalinizing trabecular adenoma/tumor is a rare follicular-
derived, thyroglobulin-producing, thyroid neoplasm com-
posed of large trabeculae of elongated or polygonal eosi-
nophilic cells admixed with intratrabecular hyaline material
of the basal membrane type. Hyalinizing trabecular tumors
share many nuclear features of those of papillary thyroid
carcinoma, namely nuclear clearing, grooves, pseudoinclu-
sions, and irregular borders [1]. This tumor was described
as a benign follicular tumor (a single malignant case is on
record among 118 benign hyalinizing trabecular tumors
reviewed some years ago) [2, 3] and was variably named, as
either adenoma or tumor or neoplasm of uncertain malig-
nant potential. No etiological or risk factors are known for
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hyalinizing trabecular tumor and a real understanding of its
nature is missing [2]. An association with papillary carci-
nomas is reported in up to 5% of cases and hyalinizing
trabecular tumor itself has been related to papillary thyroid
carcinoma based on shared morphological features and
RET gene alterations in a fraction of cases [4, 5]. Besides
RET–PTC rearrangements, no other papillary thyroid
carcinoma-related genetic abnormalities, such as BRAF
mutations [6] or microRNA expression [7, 8], have been
described in association with hyalinizing trabecular tumor.
Similarly, no follicular tumor-related alterations were
found, including RAS gene mutations or PAX8–PPARG
rearrangements, the latter originally claimed to be specific
of follicular carcinomas [9].
Very recently, Nikiforova et al. [10] have reported on the
presence of gene fusions involving PAX8 and GLIS genes as
pathognomonic genomic features underlying hyalinizing tra-
becular tumor. These fusions, in particular the PAX8–GLIS3
rearrangement, were identified in 100% of tumors with car-
dinal unequivocal morphological and immunophenotypical
features of hyalinizing trabecular tumors. By performing a
thorough genomic characterization of this entity, the same
authors were also able to show that the hyalinizing trabecular
tumor typically shows a quiet genome with a low number of
somatic mutations and no significant DNA copy number
alterations [10].
In this study, we provide a thorough independent vali-
dation of the presence of the PAX8–GLIS3 fusion in a large
multi-institutional series of 34 hyalinizing trabecular tumors,
as opposed to its absence in 237 control thyroid neoplasms
that also included 15 trabecular tumors of follicular deriva-
tion highly resembling hyalinizing trabecular tumor from a
morphological standpoint, thus posing a potential diagnostic
interpretational issue in both histopathologic and fine needle
aspiration cytology diagnostic practice.
Material and methods
Cases
After obtaining approval by the IRBs and local research
ethics committees from the authors’ institutions, the
pathology files of the authors’ institutions (Città della Salute
Hospital and Mauriziano Hospital in Torino, Italy;
San Luigi Hospital in Orbassano-Torino, Italy; Service
of Clinical Pathology, Lausanne University Hospital,
Switzerland; IRCCS in Reggio Emilia, Italy; Cleveland
Clinic, Ohio, USA; Ottawa Hospital, Canada) were sear-
ched for a diagnosis of either “hyalinizing trabecular tumor”
or “hyalinizing trabecular adenoma” of the thyroid. Samples
were anonymized prior to the analyses. Representative
hematoxylin & eosin (H&E) and Ki67/MIB1 stained slides
of 38 hyalinizing trabecular tumors were centrally reviewed
by two pathologists with a expertize in thyroid neoplasms
(MV and MP). The diagnosis of hyalinizing trabecular
tumor was based on the strict diagnostic criteria reported in
the WHO classification of endocrine tumors of the thyroid
[1], as well as in previous publications [11, 12]. Upon
pathological review, 34 cases were unanimously diagnosed
as hyalinizing trabecular tumor; four cases were excluded
and reclassified as follicular adenomas of the trabecular or
Hurthle cell type (three tumors: # 13T, 15T, and 23T) and as
Hurthle cell carcinoma based on signs of vascular invasion
in the remaining case (# 24T) (Fig. 1).
Of the 34 hyalinizing trabecular tumors included in this
study, four (HTT02, HTT06, HTT12, and HTT33)
also contained a small, classical papillary carcinoma in the
same thyroid lobe, but topographically independent from
the hyalinizing trabecular tumor nodule. In addition, a
separate series of 237 neoplasms that represented a com-
prehensive landscape of thyroid lesions were used as con-
trols, and comprised 119 papillary carcinomas, 24 follicular
carcinomas, 13 poorly differentiated carcinomas, 25 ana-
plastic carcinomas, 15 medullary carcinomas, 18 Hurthle cell
tumors, and 23 follicular adenomas (Fig. 1). Within this
series, 15 tumors showed morphological features highly
reminiscent of a hyalinizing trabecular tumor, i.e., prominent
solid/trabecular growth pattern and more or less extensive
hyalinization. These were appropriately classified in different
categories (i.e., follicular adenomas of trabecular/embryonal
variant, solid/trabecular variant of papillary carcinomas,
Hurthle cell adenomas, and Hurthle cell carcinoma).
First, eight hyalinizing trabecular tumors were subjected
as a discovery series to RNA- and DNA-sequencing
(Fig. 1). Subsequently, a validation series of 26 hyaliniz-
ing trabecular tumors were subjected to reverse transcription
(RT)-PCR and fluorescence in situ hybridization analyses
(Fig. 1).
Microdissection and nucleic acid extraction
Eight-micron-thick sections were cut from formalin-fixed
paraffin-embedded blocks of the tumor and normal thyroid
tissue, stained with nuclear fast red and microdissected
under a stereomicroscope as previously described [13]
to ensure >80% of tumor cells content and that the
normal tissue was devoid of neoplastic cells. RNA and
genomic DNA were extracted and quantified as previously
described [14].
Immunohistochemistry
Four-micron-thick sections were cut from the representative
formalin-fixed paraffin-embedded block of the 34 hyali-
nizing trabecular tumor and of the 15 tumors showed
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morphological features highly reminiscent of a hyalinizing
trabecular tumor, as well as from tissue microarrays blocks
containing the remaining 222 control thyroid neoplasms.
Slides were processed for Ki67 immunohistochemistry
with an automatic immunostainer (Ventana BenchMark
AutoStainer, Ventana Medical Systems, Tucson, USA),
with the exception of the primary antibody incubation step,
which was manually performed at room temperature for
30 min using the Ki67 clone MIB1 (Dako/Agilent,
Glostrup, Denmark) diluted 1/50, after antigen retrieval
with the commercial Ventana CC1 solution for 36 min. The
evaluation of Ki67 relied on a qualitative assessment of the
staining pattern (membranous vs. nuclear).
Whole-exome and targeted massively parallel
sequencing
Microdissected tumor and normal DNA samples from eight
hyalinizing trabecular tumors (discovery set) were subjected
to whole-exome sequencing (WES, n= 3) [15] and to
Memorial Sloan Kettering-Integrated Mutation Profiling of
Actionable Cancer Targets (MSK-IMPACT) sequencing
(n= 5; Fig. 1), which targets all exons and selected introns of
410 cancer genes, as previously described [16, 17] (Supple-
mentary Table S1). Three additional cases from the validation
set were also subjected to MSK-IMPACT (Fig. 1).
Analysis of sequencing data was performed as previously
described [15, 17]. In brief, somatic single-nucleotide var-
iants were detected using MuTect (v1.0) [18], and small
insertion and deletions (indels) by Strelka (v2.0.15) [19],
VarScan2 (v2.3.7) [20], Lancet (v1.0.0) [21], and Scalpel
(v0.5.3) [22]. Single-nucleotide variants and indels for
which the tumor mutant allele fraction was <5 times that of
the matched normal mutant allele fraction were excluded.
Single-nucleotide variants and indels found at >1% global
minor allele frequency in ExAC [23], as well as common
SNPs reported in dbSNP (build 150) were also excluded.
Copy number alterations and loss of heterozygosity were
defined using FACETS [24]. ABSOLUTE (v1.0.6) [25] was
employed to determine the cancer cell fraction of each
mutation, as previously described [15, 17]. A mutation was
classified as clonal if its probability of being clonal was
>50% or if the lower bound of the 95% confidence interval
of its cancer cell fraction was >90%, as previously descri-
bed [15, 17]. Mutations affecting hotspot codons were
annotated according to Chang et al. [26].
RNA-sequencing and fusion gene identification
RNA-sequencing was performed on eight hyalinizing tra-
becular tumors (Fig. 1, Supplementary Table S1) using
validated protocols [15] employed at MSKCC’s Integrated
Genomics Operation (IGO). In brief, paired-end RNA-
sequencing was performed with 2 × 50 bp cycles on an
Illumina HiSeq2000. Read pairs supporting fusion tran-
scripts were identified using INTEGRATE [27], deFuse
[28], and FusionCatcher [29], as previously described
[15, 30]. To account for alignment artifacts and normal
transcriptional variants, we excluded fusion gene and read-
through candidates that were also identified in a set of 297
Fig. 1 Schematic representation of the tissue samples and sequencing
methods employed in this study. Depiction of the discovery and of the
validation series of hyalinizing trabecular tumors of the thyroid, and
the comprehensive series of other thyroid neoplasms here investigated,
including 15 cases (*) in which the morphological features were highly
reminiscent of a hyalinizing trabecular tumors. The sequencing ana-
lysis methods utilized in each cohort are detailed
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normal samples from The Cancer Genome Atlas [31]. The
remaining in-frame candidate fusion genes were annotated
using OncoFuse [32] to define their likelihood of con-
stituting potential driver fusion genes. The presence of the
in-frame candidate fusion genes identified was also assessed
across 33 cancer types in the tumor fusion gene data portal
[33] that comprises a list of 20,231 fusion genes.
PAX8–GLIS3 fluorescence in situ hybridization
analysis
PAX8–GLIS3 fusion gene assessment by fluorescence
in situ hybridization was performed using validated proto-
cols at MSKCC’s Molecular Cytogenetics Core, as pre-
viously described [34]. Three-color PAX8–GLIS3 probe
was employed, consisting of bacterial artificial chromo-
somes mapping to 5′PAX8 (green), 3′PAX8 (red), and 3′
GLIS3 (orange). At least ten images per tumor region were
captured and at least 50 nonoverlapping interphase nuclei
with well-delineated contours were analyzed for the pre-
sence of the PAX8–GLIS3 fusion. Hyalinizing trabecular
tumors were considered positive for the PAX8–GLIS3
fusion gene if >15% of the cells displayed at least one 5′
PAX8–3′GLIS3 fusion signal.
RT-PCR
Total RNA was reverse-transcribed using SuperScript Vilo
Master Mix (Life Technologies; Thermo Fisher Scientific),
according to the manufacturer’s instructions. PCR amplifi-
cation of 10 ng of cDNA was performed using specific
primer sets designed based on the known fusion genes and
breakpoints (Supplementary Table S2). PCR fragments
were purified (ExoSAP-IT, Affymetrix) and sequenced on
an ABI 3730 capillary sequencer using the ABI BigDye
Terminator chemistry (v3.1, Life Technologies) according
to the manufacturer’s protocol. Sequences of the forward
and reverse strands were analyzed using MacVector soft-




All 34 hyalinizing trabecular tumors included in this study
displayed the cardinal morphological features of hyalinizing
trabecular tumors: a growth pattern made of thick trabecu-
lae; elongated or, more rarely, polygonal cells arranged with
a perpendicular orientation compared to the trabecular axis;
eosinophilic cytoplasm and clear nuclei with irregular bor-
ders, grooves, and pseudoinclusions; and finally the pre-
sence of more or less abundant hyaline material typically
intratrabecular and often embedding single or groups of
tumor cells (Fig. 2). In addition, all hyalinizing trabecular
tumors displayed immunoreactivity at the cell membrane
for the MIB1 monoclonal antibody to Ki67 (Fig. 2).
The 237 control cases, whose histology is detailed in
Supplementary Table S3, had the expected morphology for
each single tumor entity, with the exception of 15 selected
cases that had a prominent solid and/or trabecular growth
pattern and more or less extensive signs of hyalinization
that resembled a hyalinizing trabecular tumor, but were
Fig. 2 Representative
micrographs of hyalinizing
trabecular tumors of the thyroid.
A 3-mm large well-
circumscribed hyalinizing
trabecular tumor (a) showing
tumor cells arranged in
trabeculae and small nests with
abundant intratrabecular hyaline
material (b), and another
classical case of hyalinizing
trabecular tumor (c) showing
elongated and spindle cells with
nuclear palisading and hyaline
material in the background
displaying the unique cell
membrane reactivity with the
MIB1 monoclonal antibody
against Ki67 (d)
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eventually classified as variants of follicular adenoma (tra-
becular/embryonal variant, n= 8), Hurthle cell adenoma
(solid/trabecular patterns, n= 2), papillary carcinoma
(solid/trabecular variant, n= 3), Hurthle cell carcinoma
(solid/trabecular patterns, n= 1), and poorly differentiated
carcinoma (trabecular variant, n= 1) (Fig. 1). In all such
cases, a hyalinizing trabecular tumor was originally sus-
pected or diagnosed, based on the trabecular growth pattern
and the presence of stromal hyaline material. The trabeculae
were generally thin and merged, however, with compact
solid nests made of cells haphazardly oriented along the
axis of the cords (rather than perpendicularly) and with a
deeply eosinophilic and granular cytoplasm, as commonly
seen in Hurthle cells neoplasms. In addition, it is important
to note that the variable degree of hyaline material observed
in these cases was restricted to the space between the tra-
beculae and was not distributed inside them: indeed, a
typical feature of hyalinizing trabecular tumors is repre-
sented by the tight contact of such material to the neoplastic
cells. Finally, in all other thyroid neoplasms included the
diagnosis of hyalinizing trabecular tumor was not supported
due to the lack of the peculiar cell membrane reactivity
pattern for Ki67/MIB1 (Fig. 3). Similarly, none of the other
control thyroid neoplasms (n= 222) showed the peculiar
cell membrane reactivity pattern for Ki67/MIB1.
Mutational landscape and copy number alterations
in hyalinizing trabecular tumors
To assess the somatic genetic alterations, three and eight
cases were subjected to WES (median depth of coverage of
tumor 139× (range 137× to 164×) and normal 151× (range
131× to 161×) samples) and targeted MSK-IMPACT
sequencing (median depth of coverage of tumor 311×
(range 18× to 499×) and normal 174× (range 41× to 530×)
samples), respectively (Supplementary Table S4).
Hyalinizing trabecular tumors displayed a low tumor
burden, with a median of 16 (range 10–22) somatic muta-
tions defined by WES, of which 11 (range 9–19) were
nonsynonymous, while the MSK-IMPACT assay detected a
median of 1 (range 1–2) somatic mutations of which 1
(range 1–2) was nonsynonymous. No recurrent somatic
mutations were identified in the hyalinizing trabecular
tumors analyzed. The majority of mutations were non-
pathogenic missense mutations not affecting hotspot resi-
dues, and four hyalinizing trabecular tumors subjected to
MSK-IMPACT sequencing did not harbor any mutations
affecting the 410 cancer-related genes tested (Supplemen-
tary Figure S1). The potentially pathogenic nonsynonymous
mutations identified included a subclonal FIP1L1 (p.L26R)
missense mutation and a clonal ITK (p.R581W) missense
mutation in HTT10 and HTT11, respectively. Analysis
from MSK-IMPACT demonstrated a subclonal SPEN
(p.P1892Qfs*6) frameshift mutation and a clonal KDM5A
(p.R719H) missense mutation in HTT01, and a subclonal
TP63 (p.X549) splice site mutation in HTT08 (Supple-
mentary Fig. S1, Supplementary Table S5).
Copy number analysis revealed a diploid/near-diploid
genome in the 11 hyalinizing trabecular tumors (Supple-
mentary Fig. S2). No homozygous deletions or high-level






The figure illustrates a follicular
adenoma of trabecular variant
(a, 200×), a poorly differentiated
thyroid carcinoma (b, 200×),
and a Hurthle cell carcinoma (c,
200×) with prominent
hyalinization, mimicking
hyalinizing trabecular tumors on
morphological ground. No
membrane Ki67/MIB1 staining
was observed, as exemplified
here for the case of follicular
thyroid adenoma with trabecular
features (d, 200×)
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PAX8–GLIS3 fusion detection and validation in
hyalinizing trabecular tumors
Based on the initial findings of a quiet genome and lack of
recurrent pathogenic somatic mutations, the eight hyaliniz-
ing trabecular tumors of our discovery series were subjected
to global RNA-sequencing analysis, which detected the
presence of a recurrent, in-frame PAX8–GLIS3 fusion gene
(8/8, 100%), resulting in a chimeric transcript composed of
exons 1–2 of PAX8 and exons 3–11 of GLIS3 (Fig. 4a,
Supplementary Table S2). The fusion of exons 1–2 of PAX8
to the 3′-end of GLIS3 results in the increased expression of
exons 3–11 of GLIS3, as assessed using the RPKM counts
(Fig. 4b). In the eight hyalinizing trabecular tumors and in a
validation series of 26 hyalinizing trabecular tumors, the
PAX8–GLIS3 fusion gene was confirmed/presented by
fluorescence in situ hybridization (n= 12) and/or RT-PCR
(n= 33) in all hyalinizing trabecular tumors (100%; Fig. 4c,
d, Supplementary Table S3). Four hyalinizing trabecular
tumors had a concurrent papillary carcinoma, and whilst the
PAX8–GLIS3 fusion gene was present in the hyalinizing
trabecular tumor, it was absent in the papillary carcinoma of
these cases (Fig. 5).
Of note, none of the eight cases subjected to RNA-
sequencing harbored RET/PTC rearrangements.
Lack of PAX8–GLIS3 fusions in thyroid neoplasms
To determine whether PAX8–GLIS3 rearrangements would
constitute a pathognomonic genetic alteration in the hyali-
nizing trabecular tumors, fluorescence in situ hybridization
and RT-PCR were performed in the series of 237 control
cases, which included the whole spectrum of conventional
thyroid neoplasms and also encompassed a subgroup of 15
tumors of follicular derivation characterized by a prominent
trabecular growth and hyalinization that was reminiscent of
a hyalinizing trabecular tumor on sole morphological
ground. None of these controls and potential differential
diagnoses of hyalinizing trabecular tumor harbored the
PAX8–GLIS3 rearrangement (Fig. 4e, Supplementary
Table S3). In addition, none of the 9950 tumors from 33
cancer types from The Cancer Genome Atlas [33] were
found to harbor the specific PAX8–GLIS3 fusion (Fig. 4f).
These data provide evidence to suggest that the PAX8–
GLIS3 fusion is pathognomonic for hyalinizing trabecular
tumors.
Discussion
Here we present a validation of the recently reported PAX8–
GLIS3 rearrangement [10] as a hallmark genomic feature of
the rare hyalinizing trabecular tumor of the thyroid. In
agreement with Nikiforova et al. [10] findings, all of the 34
histologically proven hyalinizing trabecular tumors of the
present study harbored the PAX8–GLIS3 fusion. This gene
rearrangement has been consistently demonstrated by dif-
ferent techniques, using specifically designed probes, which
confirmed the occurrence of such rearrangement. In parallel,
this fusion gene was not present in control thyroid tumors of
various histologies, including an interesting series of tra-
becular tumors of follicular derivation that was specifically
selected from our files for the purpose of testing the power
of this novel fusion, as a potential differential diagnostic
marker.
The origin of the hyalinizing trabecular tumor is
unknown. No risk factors have been reported and the
claimed relationship with papillary thyroid carcinoma had
been challenged by the absence of BRAF mutations [6], and
now definitely excluded by the specific PAX8–GLIS3 rear-
rangement (or PAX8–GLIS1, as reported by Nikiforova
et al. [10]), that never occurred in the 300 papillary cancers
so far analyzed in published and in the present series, with
one exception in the Nikiforova’s series and in the The
Cancer Genome Atlas series of 484 papillary carcinomas
[35]. The case regarded a trabecular tumor focally remi-
niscent of a hyalinizing trabecular tumor that was eventually
diagnosed as a papillary carcinoma and probably represents
the same case used in the two different publications [10].
With regard to follicular adenoma and carcinoma, the
similarities with hyalinizing trabecular tumor are even more
scant on both morphological and genetic grounds. Besides
RAS gene mutations, follicular adenomas and carcinomas
were found to harbor a rearrangement of PAX8–PPARG
genes that was originally reported to be restricted to
malignant conditions, only [9], but subsequently identified
also in a fraction of follicular adenomas, although never in
hyalinizing trabecular tumors. Interestingly, the novel hya-
linizing trabecular tumor-specific fusion is also correlated to
the PAX8 gene, although the fusion occurred with another
locus, mapping to chromosome 9p24.2 to produce the
PAX8–GLIS3 rearrangement, or to chromosome 1 in the
case of the rarer GLIS1 type fusion [10].
Although the newly discovered genetic alteration may
not bear any impact in the therapeutic strategy of the
patients, since surgery is generally sufficient to cure the
tumor, the novel fusion product represents a relevant diag-
nostic tool of this rare tumor in surgical samples and, in
particular, in preoperative cytology specimens, in which the
diagnosis of hyalinizing trabecular tumor is reached in no
more than 8% of cases [36]. In fact, the differential diag-
nosis from solid/trabecular variants of papillary carcinoma
may occasionally pose problems due to the overlapping
nuclear features of the two tumors, while genetically the
two entities seem unrelated with a predominance of BRAF
and RAS gene mutations in papillary cancer, but not in
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Fig. 4 Recurrent PAX8–GLIS3 fusion gene in hyalinizing trabecular
tumors of the thyroid. a Schematic representation of the PAX8–GLIS3
fusion transcript including the exons and domains involved. The
breakpoint of the 5′ and 3′ partner genes are represented as black
vertical lines. Spanning reads are depicted and aligned to the predicted
junction sequence. b Schematic representation the Reads Per Kilobase
per Million (RPKM) mapped read counts of each exon of GLIS3. The
GLIS3 fusion breakpoint is represented as a red dashed line.
c Representative micrographs of fluorescent in situ hybridization for
PAX8–GLIS3. d A representative Sanger sequencing electropherogram
of the genomic PAX8–GLIS3 breakpoint (top) and frequency of
PAX8–GLIS3 fusion gene in hyalinizing trabecular tumors involved in
this study determined by RT-PCR (bottom). e Frequency of the PAX8–
GLIS3 fusion gene in hyalinizing trabecular tumors and other thyroid
neoplasms of the control cohort determined by RT-PCR. AC ana-
plastic carcinomas, FA follicular adenomas, FC follicular carcinomas,
HCT hurthle cell tumors, HTT hylinizing trabecular tumors, MC
medullary carcinomas, PDC poorly differentiated carcinomas, PTC
papillary thyroid carcinomas. f Frequency of PAX8–GLIS3 fusion gene
in hyalinizing trabecular tumors analyzed in this study and by
Nikiforova et al., and other neoplasms as reported by The Cancer
Genome Atlas fusion gene database. HTT hyalinizing trabecular
tumor, ACC adrenocortical carcinoma, BLCA bladder urothelial car-
cinoma, BRCA breast invasive carcinoma, CESC cervical squamous
cell carcinoma and endocervical adenocarcinoma, CHOL cholangio-
carcinoma, COAD colon adenocarcinoma, DLBC lymphoid neoplasm
diffuse large B-cell lymphoma, ESCA esophageal carcinoma, GBM
glioblastoma multiforme, HNSC head and neck squamous cell carci-
noma, KICH kidney chromophobe, KIRC kidney renal clear cell
carcinoma, KIRP kidney renal papillary cell carcinoma, LAML acute
myeloid leukemia, LGG brain lower grade glioma, LIHC liver hepa-
tocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung
squamous cell carcinoma, MESO mesothelioma, OV ovarian serous
cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PCPG
pheochromocytoma and paraganglioma, PRAD prostate adenocarci-
noma, READ rectum adenocarcinoma, SARC sarcoma, SKCM skin
cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testi-
cular germ cell tumors, THCA thyroid carcinoma, THYM thymoma,
UCEC uterine corpus endometrial carcinoma, UCS uterine carcino-
sarcoma, UVM uveal melanoma
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hyalinizing trabecular tumors [6]. In addition, even folli-
cular neoplasms may resemble a hyalinizing trabecular
tumor when the growth pattern is predominantly trabecular
or solid, as seen in embryonal/fetal type follicular adenomas
or in poorly differentiated carcinomas. The commonly
shared thyroglobulin production is of no help in this setting
of differential diagnosis, and the only useful hyalinizing
trabecular tumor marker is the peculiar membrane pattern
(artefactually) produced by Ki67 immunostaining, provided
specific technical conditions are met (i.e., use of MIB1
monoclonal and room temperature incubation), in order to
obtain the expected cell membrane reactivity [37].
Although diagnostic criteria for both hyalinizing trabe-
cular tumors and its mimickers are apparently clear-cut, it is
the experience of some of us that in the daily consultation
practice, a certain degree of confusion exists among the
different entities. The major source of controversies is the
presence of more or less hyalinized stroma in an otherwise
trabecular or solid/compact tumor cell proliferation of fol-
licular derivation. Such a pattern of growth is shared by
several primary tumors of various nature, including not only
by follicular tumors (embryonal adenoma, solid variant of
papillary carcinoma, Hurthle cell neoplasms, poorly differ-
entiated carcinoma), but also by medullary carcinoma and
intrathyroid parathyroid tumors. Apart from the differences
in cell type and, obviously, in the ultimate immunoprofile of
tumor cells, the trabecular structure is crucial for a diagnosis
of a hyalinizing trabecular tumor: thick cords of elongated
cells, arranged perpendicular to the major axis of the tra-
becula itself, contain variable amounts of hyaline col-
lagenized material inside the trabeculae, to surround
individual tumor cells. The general impression is that of a
paraganglioma rather than a trabecular follicular-derived
tumor, but the extent of hyalinization may change the
overall picture and cause misdiagnoses. Indeed, all 15 tra-
becular cases, including four originally submitted as hyali-
nizing trabecular tumors, that we deliberately selected
among the control cases lacked the PAX8–GLIS3 fusion.
This supports the notion that the spectrum of trabecular
thyroid neoplasms is relatively wide and heterogeneous,
including a variety of growth patterns in which thick
trabeculae merge with hyaline material depicting in the end
more than one specific follicular derived, benign or malig-
nant, entity or subtype. The novel described PAX8–GLIS3
fusion is a valuable hint to take the hyalinizing trabecular
tumor apart from its mimickers.
Interestingly, four hyalinizing trabecular tumors cases
had associated small papillary carcinomas, which did
not harbor the GLIS3 fusion product. In addition, in the
Nikiforova’s study [10] a link with upregulation of genes
implicated in collagen type IV deposition was suggested, as
the result of the gene rearrangement involving chromo-
somes 2 and 9, although the exact mechanisms remain to be
elucidated. The abundance of basal membrane type material
included collagen IV had been reported in prior immuno-
histochemical studies by Li and Rosai [38] and Papotti et al.
[12]. These molecular and morphological findings may be
of further help in taking apart real hyalinizing trabecular
tumors from all the mimickers discussed above, care being
taken to identify a predominant intratrabecular collagen
deposition (rather than in the neoplastic stroma), since such
a material seems to be the direct result of collagen-related
gene upregulation in the fusion-positive neoplastic cells.
Finally, as demonstrated by Nikiforova et al. [10, 39]
using ThyroSeq v3 gene panel in over 10,000 FNABs, this
novel fusion may represent a relevant diagnostic marker of
hyalinizing trabecular tumor in preoperative fine needle
aspiration biopsies, especially to take it apart from other
solid/trabecular thyroid tumors with prominent hyaliniza-
tion. A correct preoperative characterization of hyalinizing
trabecular tumors can result from molecular methods or
from immunohistochemistry for GLIS3, to refrain from
unnecessary surgery of indeterminate cytology trabecular/
follicular nodules harboring the PAX8–GLIS3 fusion.
Indeed, a proper diagnosis of hyalinizing trabecular tumor
especially with respect to papillary thyroid carcinoma has
important clinical implications, which are heavily related to
the type of surgical strategy (since radical resection may not
be necessary in hyalinizing trabecular tumor), as well as
with the type of follow up or subsequent treatment (as no
radiometabolic treatment is required in case of hyalinizing
trabecular tumor).
Fig. 5 Co-occurrence of a papillary thyroid carcinoma and a hyali-
nizing trabecular tumor in a single patient. The scanned histological
section contains a small papillary carcinoma (2 mm, dashed circle line)
and a hyalinizing trabecular tumor (main lesion, dashed semicircular
line). Fluorescence in situ hybridization was performed and selected
fields were scanned within the two lesions, thus demonstrating PAX8–
GLIS3 fusions in the hyalinizing trabecular tumor (a), whereas no
rearrangements were appreciated in the papillary carcinoma (b)
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In conclusion, the hyalinizing trabecular tumor repre-
sents a unique tumor based on its morphological (intra-
trabecular hyalinization, papillary cancer-like nuclei),
immunohistochemical (Ki67/MIB1 expression at the cell
membrane) and now also molecular (PAX8–GLIS3 fusion)
features. The latter support the notion of separately classi-
fying this tumor probably representing a peculiar variety of
GLIS-rearranged hyalinizing trabecular adenoma. This is
consistent with the original proposal by Carney et al. [11],
who separated this tumor from both papillary carcinomas
and the other conventional follicular thyroid neoplasms.
Acknowledgements This work was supported by grants from the
Associazione Italiana Ricerca sul Cancro (AIRC, Milan, no. IG
20100 to MP), the Italian Ministry of Education, University and
Research (MIUR ex-60%-2017, 2015HAJH8E and FPRC 5xmille
2015 MIUR-“Progetto Futuro” to CM). LA is funded by Fondazione
Umberto Veronesi. We also acknowledge the funding by MIUR
project “Dipartimenti di Eccellenza 2018–2022” (Project no.
D15D18000410001) to the Department of Medical Sciences of the
University of Turin, Italy. JSR-F is funded by Breast Cancer
Research Foundation. Research reported in this publication was
funded in part by a Cancer Center Support Grant of the National
Institutes of Health/National Cancer Institute (grant no.
P30CA008748). The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health. The funders of this study had no role in
the design of the study; the collection, analysis, and interpretation of
the data; the writing of the manuscript; and the decision to submit the
manuscript for publication.
Compliance with ethical standards
Conflict of interest CM has received personal/consultancy fees from
Axiom Healthcare Strategies, Daiichi-Sankyo, and Bayer, outside the
scope of the submitted work. JSR-F reports personal/consultancy fees
from VolitionRx, Page.AI, Goldman Sachs, Grail, Ventana Medical
Systems, Roche and Genentech, outside the scope of the submitted
work. All remaining authors have no conflicts of interest to declare.
Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
References
1. Jeong KJ, Park SY, Cho KH, Sohn JS, Lee J, Kim YK, et al. The
Rho/ROCK pathway for lysophosphatidic acid-induced proteoly-
tic enzyme expression and ovarian cancer cell invasion. Onco-
gene. 2012;31:4279–89.
2. Carney JA, Hirokawa M, Lloyd RV, Papotti M, Sebo TJ. Hyali-
nizing trabecular tumors of the thyroid gland are almost all
benign. Am J Surg Pathol. 2008;32:1877–89.
3. Gowrishankar S, Pai SA, Carney JA. Hyalinizing trabecular car-
cinoma of the thyroid gland. Histopathology. 2008;52:529–31.
4. Cheung CC, Boerner SL, MacMillan CM, Ramyar L, Asa SL.
Hyalinizing trabecular tumor of the thyroid: a variant of papillary
carcinoma proved by molecular genetics. Am J Surg Pathol.
2000;24:1622–6.
5. Papotti M, Volante M, Giuliano A, Fassina A, Fusco A, Bussolati
G, et al. RET/PTC activation in hyalinizing trabecular tumors of
the thyroid. Am J Surg Pathol. 2000;24:1615–21.
6. Salvatore G, Chiappetta G, Nikiforov YE, Decaussin-Petrucci M,
Fusco A, Carney JA, et al. Molecular profile of hyalinizing tra-
becular tumours of the thyroid: high prevalence of RET/PTC
rearrangements and absence of B-raf and N-ras point mutations.
Eur J Cancer. 2005;41:816–21.
7. Sheu SY, Vogel E, Worm K, Grabellus F, Schwertheim S, Schmid
KW. Hyalinizing trabecular tumour of the thyroid-differential
expression of distinct miRNAs compared with papillary thyroid
carcinoma. Histopathology. 2010;56:632–40.
8. Acquaviva G, Visani M, Repaci A, Rhoden KJ, de Biase D,
Pession A, et al. Molecular pathology of thyroid tumours of fol-
licular cells: a review of genetic alterations and their clin-
icopathological relevance. Histopathology. 2018;72:6–31.
9. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman
BM, et al. PAX8-PPARgamma1 fusion oncogene in human
thyroid carcinoma [corrected]. Science. 2000;289:1357–60.
10. Nikiforova MN, Nikitski AV, Panebianco F, Kaya C, Yip L,
Williams M, et al. GLIS rearrangement is a genomic hallmark of
hyalinizing trabecular tumor of the thyroid gland. Thyroid.
2019;29:161–73.
11. Carney JA, Ryan J, Goellner JR. Hyalinizing trabecular adenoma
of the thyroid gland. Am J Surg Pathol. 1987;11:583–91.
12. Papotti M, Riella P, Montemurro F, Pietribiasi F, Bussolati G.
Immunophenotypic heterogeneity of hyalinizing trabecular
tumours of the thyroid. Histopathology. 1997;31:525–33.
13. Marchio C, Geyer FC, Ng CK, Piscuoglio S, De Filippo MR,
Cupo M, et al. The genetic landscape of breast carcinomas with
neuroendocrine differentiation. J Pathol. 2017;241:405–19.
14. Guerini-Rocco E, Hodi Z, Piscuoglio S, Ng CK, Rakha EA,
Schultheis AM, et al. The repertoire of somatic genetic alterations
of acinic cell carcinomas of the breast: an exploratory, hypothesis-
generating study. J Pathol. 2015;237:166–78.
15. Pareja F, Lee JY, Brown DN, Piscuoglio S, Gularte-Merida R,
Selenica P, et al. The genomic landscape of mucinous breast
cancer. J Natl Cancer Inst. 2019;111:djy216.
16. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al.
Mutational landscape of metastatic cancer revealed from pro-
spective clinical sequencing of 10,000 patients. Nat Med.
2017;23:703–13.
17. Geyer FC, Li A, Papanastasiou AD, Smith A, Selenica P, Burke
KA, et al. Recurrent hotspot mutations in HRAS Q61 and PI3K-
AKT pathway genes as drivers of breast adenomyoepitheliomas.
Nat Commun. 2018;9:1816.
18. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D,
Sougnez C, et al. Sensitive detection of somatic point mutations in
impure and heterogeneous cancer samples. Nat Biotechnol.
2013;31:213–9.
19. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ,
Cheetham RK. Strelka: accurate somatic small-variant calling
from sequenced tumor-normal sample pairs. Bioinformatics.
2012;28:1811–7.
20. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L,
et al. VarScan 2: somatic mutation and copy number alteration
discovery in cancer by exome sequencing. Genome Res. 2012;22:
568–76.
21. Narzisi G, Corvelo A, Arora K, Bergmann EA, Shah M, Musunuri
R, et al. Genome-wide somatic variant calling using localized
colored de Bruijn graphs. Commun Biol. 2018;1:20.
22. Narzisi G, O’Rawe JA, Iossifov I, Fang H, Lee YH, Wang Z,
et al. Accurate de novo and transmitted indel detection in exome-
capture data using microassembly. Nat Methods. 2014;11:
1033–6.
23. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E,
Fennell T, et al. Analysis of protein-coding genetic variation in
60,706 humans. Nature. 2016;536:285–91.
1742 C. Marchiò et al.
24. Shen R, Seshan VE. FACETS: allele-specific copy number and
clonal heterogeneity analysis tool for high-throughput DNA
sequencing. Nucleic Acids Res. 2016;44:e131.
25. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T,
et al. Absolute quantification of somatic DNA alterations in
human cancer. Nat Biotechnol. 2012;30:413–21.
26. Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue
MTA, Jonsson P, et al. Accelerating discovery of functional
mutant alleles in cancer. Cancer Discov. 2018;8:174–83.
27. Zhang J, White NM, Schmidt HK, Fulton RS, Tomlinson C, Warren
WC, et al. INTEGRATE: gene fusion discovery using whole gen-
ome and transcriptome data. Genome Res. 2016;26:108–18.
28. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun
MG, et al. deFuse: an algorithm for gene fusion discovery in
tumor RNA-Seq data. PLoS. 2011;7:e1001138.
29. Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V,
Kleivi K, et al. Identification of fusion genes in breast cancer by
paired-end RNA-sequencing. Genome Biol. 2011;12:R6.
30. Piscuoglio S, Burke KA, Ng CK, Papanastasiou AD, Geyer FC,
Macedo GS, et al. Uterine adenosarcomas are mesenchymal
neoplasms. J Pathol. 2016;238:381–8.
31. Cancer Genome Atlas Network. Comprehensive molecular por-
traits of human breast tumours. Nature. 2012;490:61–70.
32. Shugay M, Ortiz de Mendibil I, Vizmanos JL, Novo FJ. Onco-
fuse: a computational framework for the prediction of the onco-
genic potential of gene fusions. Bioinformatics. 2013;29:2539–46.
33. Hu X, Wang Q, Tang M, Barthel F, Amin S, Yoshihara K,
et al. TumorFusions: an integrative resource for cancer-
associated transcript fusions. Nucleic Acids Res. 2018;46:
D1144–9.
34. Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L,
Cyrta J, et al. Genomic landscape of adenoid cystic carcinoma of
the breast. J Pathol. 2015;237:179–89.
35. Cancer Genome Atlas Network. Integrated genomic character-
ization of papillary thyroid carcinoma. Cell. 2014;159:676–90.
36. Saglietti C, Piana S, La Rosa S, Bongiovanni M. Hyalinizing
trabecular tumour of the thyroid: fine-needle aspiration cytolo-
gical diagnosis and correlation with histology. J Clin Pathol.
2017;70:641–7.
37. Leonardo E, Volante M, Barbareschi M, Cavazza A, Dei Tos AP,
Bussolati G, et al. Cell membrane reactivity of MIB-1 antibody to
Ki67 in human tumors: fact or artifact? Appl Immunohistochem
Mol Morphol. 2007;15:220–3.
38. Li M, Carcangiu ML, Rosai J. Abnormal intracellular and extra-
cellular distribution of basement membrane material in papillary
carcinoma and hyalinizing trabecular tumors of the thyroid:
implication for deregulation of secretory pathways. Hum Pathol.
1997;28:1366–72.
39. Nikiforova MN, Mercurio S, Wald AI, Barbi de Moura M, Call-
enberg K, Santana-Santos L, et al. Analytical performance of the
ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid
nodules. Cancer. 2018;124:1682–90.
Affiliations
Caterina Marchiò1,2 ● Arnaud Da Cruz Paula3 ● Rodrigo Gularte-Merida 4 ● Thais Basili 4 ● Alissa Brandes4 ●
Edaise M. da Silva4 ● Catarina Silveira 4 ● Lorenzo Ferrando 4,5 ● Jasna Metovic 6 ● Francesca Maletta6 ●
Laura Annaratone 1,2 ● Fresia Pareja4 ● Brian P. Rubin7 ● Aaron P. Hoschar7 ● Giovanni De Rosa8 ● Stefano La Rosa9 ●
Massimo Bongiovanni 9 ● Bibianna Purgina10 ● Simonetta Piana 11 ● Marco Volante12 ● Britta Weigelt4 ●
Jorge S. Reis-Filho4,13 ● Mauro Papotti6
1 Pathology Division, Candiolo Cancer Institute, FPO–IRCCS,
Candiolo, Italy
2 Department of Medical Sciences, University of Turin, Torino, Italy
3 Department of Surgery, Memorial Sloan Kettering Cancer Center,
New York, NY, USA
4 Department of Pathology, Memorial Sloan Kettering Cancer
Center, New York, NY, USA
5 Department of Internal Medicine, University of Genova,
Genova, Italy
6 Department of Oncology, University of Turin, at Città della Salute
Hospital, Torino, Italy
7 Department of Pathology, Cleveland Clinic, Cleveland, OH, USA
8 Pathology Division, Mauriziano Hospital, Torino, Italy
9 Service of Clinical Pathology, Lausanne University Hospital,
Institute of Pathology, Lausanne, Switzerland
10 Department of Pathology and Laboratory Medicine, Ottawa
Hospital, ON, Canada
11 Pathology Unit, Arcispedale Santa Maria Nuova, Azienda USL-
IRCCS, Reggio Emilia, Italy
12 San Luigi Gonzaga Hospital and Department of Oncology,
University of Turin, Orbassano, Italy
13 Human Oncology and Pathogenesis Program, Memorial Sloan
Kettering Cancer Center, New York, NY, USA
PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of. . . 1743
